Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Collegium Pharmaceutical (COLL)

Collegium Q2 revenue up 6% to $199.9 million; full-year product revenue guidance cut

Mixed Impact 4 of 5 guidance Written later

Collegium reported second-quarter 2026 product revenues of $199.9 million, up 6% from a year earlier, and a GAAP net loss of $15.1 million, compared with net income of $12.0 million a year earlier. The company completed its AZSTARYS acquisition in May, but lowered its full-year 2026 guidance for product revenues and adjusted EBITDA, citing lower-than-expected revenue from authorized generic versions of Nucynta and Nucynta ER.

Key points

  • Q2 2026 product revenues, net of $199.9 million, up 6% year over year; JORNAY PM net revenue of $46.1 million, up 41%
  • GAAP net loss of $15.1 million, or $(0.46) per share, versus GAAP net income of $12.0 million, or $0.38 per share, in Q2 2025
  • Full-year 2026 product revenues, net guidance lowered to $825 million to $855 million from $865 million to $895 million; adjusted EBITDA guidance lowered to $445 million to $470 million from $475 million to $500 million
  • AZSTARYS acquisition completed in May 2026 and generated $12.9 million in net revenue from May 12 to June 30, 2026; AZSTARYS 2026 revenue guidance raised to $65 million to $75 million

The filing

CompanyCollegium Pharmaceutical (COLL)
Form8-K, current report
Filed with the SECAug 6, 2026, 7:33 AM ET
Accession number0001628280-26-053849

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.